Summary A possible link between protein kinase C (PKC) and P-glycoprotein (P-gp)-mediated-multidrug resistance (MDR) was assumed from studies on MDR cell lines selected in vitro. The functional relevance of PKC for the MDR phenotype remains unclear, and the involvement of a particular PKC isozyme in clinically occurring drug resistance is not known. Recently, we have demonstrated significant correlations between the expression levels of the PKC'q isozyme and the MDR1 or MRP (multidrug resistance-associated protein) genes in blasts from patients with acute myelogenous leukaemia (AML) and in ascites cell aspirates from ovarian cancer patients. To extend these findings to further types of human tumours we analysed specimens from 64 patients with primary breast cancer for their individual expression levels of several MDR-associated genes (MDR1, MRP, LRP (lung cancer resistance-related protein), topoisomerase (Topo) Ila/lip, cyclin A and the PKC isozyme genes (a, P,, P21 ii, 0 and j) by a cDNA-PCR approach. We found significantly enhanced mean values for MRP, LRP and PKCn gene expression, but significantly decreased Topo Ila and cyclin A gene expression levels in G2 tumours compared with G3.
The successful treatment of breast cancer using antineoplastic agents is often limited by the occurrence of drug resistance. Studies on cell lines selected in vitro revealed different mechanisms eventually responsible for the observed multidrug resistance (MDR) , such as the overexpression of (a) the P-glycoprotein (P-gp) drug transporter (for review see Germann, 1996) , (b) the 'multidrug resistance-associated protein' (MRP) that represents another ATP-binding cassette membrane glycoprotein also transporting drug conjugates (for review see Loe et al, 1996) , (c) the 'lung cancer resistance-related protein' (LRP) that was described first in a MDR cell line lacking enhanced P-gp expression, characterized as a human major vault protein (for review see Izquierdo et al, 1996) and (4) a decreased activity of topoisomerase II (Topo II) (for review see Nitiss and Beck, 1996) .
An influence of protein kinase C (PKC) on P-gp-mediated MDR is suggested as well, but it still remains unclear how PKC or particular PKC isozymes might be functionally involved here: (a) in vitro studies on cell lines gave evidence that P-gp is directly phosphorylated by PKC (Chambers et al, 1990a,b) ; (b) co-overexpression of PKCa pointed to a possible role of this PKC isozyme in MDR of breast cancer cell lines (Yu et al, 1991) ; (c) MRPmediated MDR was significantly modulated by the specific PKC inhibitor GO 6850 ; but (d) PKC-mediated phosphorylation of P-gp seems not to be significantly associated with altered P-gp drug transport function (Scala et al, 1995; Gekeler et al, 1996; Germann et al, 1996) . Remarkably, the induction of a P-gp-mediated MDR in cell lines using different anticancer drugs (Gekeler et al, 1988; Sato et al, 1990) could be attenuated by using protein kinase inhibitors such as staurosporine, which suggested a protein kinase-triggered stress response of cells including the up-regulation at least of the human MDR1 gene (Chaudhary and Roninson, 1993; Blobe et al, 1994; Grunicke et al, 1994) .
We recently reported enhanced MDR1 and MRP gene expression levels in blasts of relapsed state AML patients, together with a significant general correlation of PKCTI with MDR1 or MRP gene expression, and, additionally, a significant correlation between PKCO and MRP gene expression levels (Beck et al, 1996a ). We also found elevated expression of the MDR1, MRP and LRP genes together with elevated PKCl mRNA levels in ascites cell aspirates obtained from ovarian cancer patients after chemotherapy (Beck et al, 1996b) . Based on these findings, we hypothesized that PKCTl could represent a key regulatory factor 87 for up-regulation of various MDR-associated genes in response to chemotherapy. To further substantiate these observations, we carried out a prospective study on primary breast cancer specimens classified Gl-G3.
MATERIALS AND METHODS Patients
We investigated solid tumour specimens from 64 women with primary breast cancer within a prospective study from January 1994 to December 1995. The median age was 58 years ranging from 37 to 88 years. A total of 35 patients showed positive node status, whereas 29 were staged as negative. Metastases were initially detectable in three patients. None of the patients received radiotherapy or chemotherapy before the collection of samples. Pathological examination showed 54 invasive ductal carcinomas, two invasive medullary carcinomas, one invasive lobular carcinoma, one carcinoma of the mucous type and six cases showed features of two different types of carcinomas simultaneously. A total of 32 tumours were classified GI, GI-2 or G2 and 32 were assigned G2-3 or G3. Histological grading (Gl = high, G2 = intermediate and G3 = low grade) was performed according to Bloom and Richardson (1957) .
Cell lines
The parental human breast cancer cell line MCF7 was obtained from the American Type Culture Collection, Rockville, MD, USA (ATCC HTB-22). It was originally derived from tumour cells from a breast cancer patient with pleural effusion. MCF7/ADR is a corresponding doxorubicin-selected P-gp overexpressing cell line (Batist et al, 1986) .
Tumour samples and RNA isolation
We obtained fresh tumour tissues from breast cancer patients when tumours were extracted during surgery. The identity of tumour tissue was evaluated with the help of a pathologist. We stored samples immediately at -80°C. RNA was isolated within 2 weeks or the probes were transferred to liquid nitrogen. To isolate whole cellular RNA, tissues were cut into small pieces immediately after thawing and were subsequently homogenized in a Potter homogenizer in the presence of 4 M guanidinium isothiocyanate prewarmed to 65°C. The solution was then loaded onto a 5.7 M solution of caesium chloride and RNA was isolated after ultracentrifugation according to Chirgwin et al (1979) .
cDNA-PCR
Conditions for cDNA synthesis and semiquantitative polymerase chain reaction (PCR) were performed, as reported previously . Briefly, cDNA was synthesized by incubation with RAV2 reverse transcriptase (9 U jig-') and PCR was performed using Taq DNA polymerase (2.5 U 200 ng-' cDNA equivalent) (both enzymes were obtained from Amersham, Braunschweig, Germany). To minimize cross-contamination, samples taken for cDNA synthesis or PCR were carefully prepared using separate solutions, pipettes and centrifuges. To rule out false positives eventually generated from genomic DNA or cross-contamination of the PCR amplified material, samples lacking reverse transcriptase were examined at fixed-time intervals. PCR products were separated by polyacrylamide gel electrophoresis and then stained with ethidium bromide. Signals were directly digitalized using the CS1 videoimager (Cybertech, Berlin, Germany) and densitometrically analysed using WINCAM software (Cybertech). The specific signals were normalized to the signals obtained using the amplimers for the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene (internal standard). This value was then referred to the corresponding value seen with material of the MDR breast cancer cell line MCF7/ADR. The expression levels of all genes included in our analysis in the material of this cell line were arbitrarily set to 100%. Experiments were carried out at least twice. Mean values were taken for further analysis. Reproducibility of experiments was generally found to be within the range of 10-20%.
Primer pairs
Primer pairs and conditions for PCR of GAPDH, MDR1, MRP, Topo 11a, Topo II and cyclin A , PKC (a, P, 2, ig, 0) (Beck et al, 1996a) , LRP and PKCj (Beck et al, 1996b) were adopted from previous studies. 
Immunohistochemistry
The P-gp content at the protein level was determined on cryostat sections from several tumour samples by immunohistochemistry (Cordell et al, 1984 ) using the MRK1 6 anti-P-gp monoclonal antibody (Syrinx, Frankfurt, Germany) together with reagents from a detection kit (Dako, Hamburg, Germany). According to the extent of P-gp expression levels found, the samples were categorized from 0 (weak) to 5 (strong).
Statistics
Statistical analysis was performed for different purposes: (a) we asked whether an altered expression of resistance-associated genes in G2 and G3 breast cancers might correspond with the differences of a clinically observed drug resistance. We therefore performed the Mann-Whitney U-test to calculate the significance of differences between the various cohorts concerning their gene expression levels. (b) In previous studies we observed correlations between the expression levels of resistance-associated genes and PKCrl in AML and in ascites aspirates from ovarian cancer patients. A similar observation was reported for Topo IlIa and cyclin A expression levels 1996a) . In the present study, we asked whether such correlations might also exist in specimens obtained from breast cancer patients. We used Spearman's rank order correlation test for these variables. To test for correlations that might include other parameters we used this test for other values determined within this study. However, statistical significance might be affected when multiple parameters are compared by increasing the probability of finding correlations just by chance. Therefore, our results from the statistical analysis should be taken as a first explorative description. Results are presented when the P-value was < 0.05 and rs exceeded > 0.500.
RESULTS
We determined the individual relative expression levels of the resistance-associated genes (MDRl, MRP, LRP, Topo IIa/II) and the PKC isozyme (a, Pi , r2, e, g) genes in 64 breast cancer specimens using a cDNA-PCR approach. In addition, we measured cyclin A gene expression levels as a marker for cellular proliferative activity (Pines and Hunter, 1990 ).
The expression analysis revealed significantly higher mean values for cyclin A and Topo Ila together with lower values for MRP, LRP and PKCrI in G3 tumours than in G2 tumours (Table 1) .
Moreover, we found significant positive correlations for MDRl/PKCrl (rs= +0.6451, P<0.0001), n = 62; MRPIPKCrT (rs = +0.5454, P<0.0001), n = 63; LRPIPKCri (rs = +0.5436, P < 0.0001) n = 62; MRPILRP (rs = +0.7703, P < 0.0001) n = 62; MDRIIMRP (r, = +0.5042, P < 0.0001) n = 62 and also between cyclin A and Topo Ilcc gene expression (rs = +0.6408, P < 0.0001) n = 64. Nothing alike was observed in the case of the PKCcx, PKCO or PKCp isozyme mRNA expression levels. Any correlations with staging of the patients according to the TNM (T, tumour size; N, lymph nodes infiltrated by tumour cells; and M, metastasis) classification were not observed. Our estimation of P-gp at the protein level determined by immunohistochemistry (data not shown) correlated significantly with the MDR1 gene expression analysis using cDNA-PCR (rs = +0.7848, P < 0.001, n = 14).
These results were obtained from statistical analysis that tested multiple parameters against each other. However, in breast cancers, the test showed highest correlations exactly for those variables we also found in previous studies in other tumour tissues. Therefore, we suggest that the results might be of importance and should provide a basis for further investigations at the functional level.
Remarkably, expression of the PKCP, and , genes was not detectable either in the primary breast cancer specimens or in material of the MCF7 cell lines by our cDNA-PCR approach applying 32 (PKC,1) or 28 (PKCP2) cycles respectively. Therefore, these genes are not listed in the table. Nonetheless, this observation might be important as distinct PKCP, and P2 gene expression was found in normal lymphocytes under the same conditions (J Beck et al, unpublished results). In fact, in a series of dilution experiments with total RNA prepared from the MCF7 cell line or normal peripheral blood mononuclear cells (PBMCs) we found distinct PKCf expression signals if the fraction of added PBMC RNA amounts only to 5%. Thus, a lack of signals corresponding to PKCf might indicate that the tumour samples did not contain significant amounts of PBMCs that may give false positives concerning MDR1 gene expression.
DISCUSSION
Standard breast cancer chemotherapeutic regimens include doxorubicin, taxol and vinblastine. Each of these compounds is included in the resistance profile of either MDRI or MRP overexpressing cells.
The functional involvement of LRP in a cellular resistance towards these drugs remains to be clarified, however. The activity of topoisomerases supposedly affects the sensitivity towards topoisomerase inhibitors such as doxorubicin, but cellular proliferation activity could influence the effects of antiproliferative drugs in general. Retrospective clinical studies showed that breast cancer tissues with high proliferation indices and a low grade of differentiation generally respond better to chemotherapy (Silvestrini and Daidone, 1993) . Our present analysis demonstrates that Topo IIcl and cyclin A gene expression levels are significantly lower in G2 than in G3 classified tumours. This corresponds well to the enhanced proliferation activity and lower differentiation grade of G3 tumours than G2 tumours, and the better response of G3 tumours to chemotherapy.
Furthermore, the MRP and LRP gene expression levels were significantly higher in G2 tumours than in G3 classified tumours.
British Journal of Cancer (1998) 77(1), [87] [88] [89] [90] [91] ,<,"A "ol, This agrees with a previous study on bladder carcinomas that revealed enhanced MRP gene expression levels in the higher differentiated GI and G2 tumours compared with G3 tumours (Clifford et al, 1996) . Thus, our results might explain the better responsiveness of G3 staged breast cancers to chemotherapeutic regimens, which may depend not only on the enhanced proliferation rate together with higher activity of Topo IIa but also on the lower expression levels of the MRP and LRP genes compared with G2 staged tumours. In contrast, the drug resistance generally seen in more differentiated primary breast cancers with lower proliferative activity appears to be mediated by multiple factors. However, it is too early to take the observed variations in gene expression levels between the G2/G3 cohorts as prognostic factors for the outcome of treatment in the case of patients included in our study because the observation period after the date of primary diagnosis is still too short.
Recently, we demonstrated in AML blasts a significant positive correlation between the PKCTI and MDR1 or MRP gene expression levels, respectively, and in addition between PKCO and MRP levels (Beck et al, 1996a) . Furthermore, we found enhanced PKCn mRNA expression together with higher expression of MDRI, MRP and LRP in ascites cell aspirates from ovarian cancer patients (Beck et al, 1996b) . Our analysis on breast cancer samples gives very similar results to these earlier studies, i.e. a significant correlation of relative PKCrI and MDR1, MRP or LRP gene expression levels, respectively. Therefore, we suggest that this particular PKC isozyme might be directly involved in either the expression status of MDR associated genes or the differentiation stage of primary breast cancer tumour cells. This hypothesis might be supported by recent findings that PKCTl is predominantly located in the cell nucleus of skin-derived human cells. Accordingly, a possible direct regulatory function of PKCl at the transcriptional level was suggested (Greif et al, 1994) .
However, other investigators have already analysed MDRl/P-gp expression in breast cancers using different methods. Although these results showed a great variability, the majority of investigators found relatively high MDRl/P-gp expression in tumours treated with drugs involved in P-gp-mediated MDR (Goldstein et al, 1989; Schneider et al, 1989; Ro et al, 1990; Sanfilippo et al, 1991) . Therefore, it seems interesting to determine whether and to what extent a possible induction of resistance-associated genes in response to chemotherapeutic regimens might be controlled by PKCrl. ABBREVIATIONS LRP, lung cancer resistance related protein; MDR, multidrug resistance; MRP, multidrug resistance-associated protein; P-gp, P-glycoprotein; PKC, protein kinase C, Topo II, topoisomerase II.
